Table 1.
Frequency distributions of HNC patient characteristics (total number of patients = 90)
| Characteristics | Number of patients (%) |
|---|---|
| Age distribution (N = 90) | |
| < 60 years | 22 (24.4) |
| ≥ 60 years | 68 (75.6) |
| Length of time since completion of HNC treatment (N = 89) | |
| < 5 years after treatment | 62 (69.7) |
| > 5 years after treatment | 27 (30.3) |
| T classification (N = 75) | |
| T1 | 17 (22.7) |
| T2 | 25 (33.3) |
| T3 | 13 (17.3) |
| T4 | 20 (26.7) |
| N classification (N = 75) | |
| N0 | 37 (49.3) |
| N1 | 11 (14.7) |
| N2 | 25 (33.3) |
| N3 | 2 (2.7) |
| M classification (N = 75) | |
| M0 | 75 (100) |
| Tumor location (N = 88) | |
| Pharynx | 45 (51.1) |
| Larynx | 23 (26.1) |
| Oral cavity | 11 (12.5) |
| Other locationa | 9 (10.2) |
| Treatment (N = 89) | |
| Definitive radiotherapy | 37 (41.6) |
| Surgery | 10 (11.2) |
| Surgery and adjuvant radio(chemo)therapy | 26 (29.2) |
| Definitive radiochemotherapy | 16 (18) |
| Tracheotomy (N = 87) | |
| Tracheotomy | 14 (16.1) |
| No tracheotomy | 73 (83.9) |
| FOIS (N = 88) | |
| Level 1 | 8 (9.1) |
| Level 2 | 9 (10.2) |
| Level 3 | 1 (1.1) |
| Level 4 | 5 (5.7) |
| Level 5 | 38 (43.1) |
| Level 6 | 14 (15.9) |
| Level 7 | 13 (14.8) |
HNC head and neck cancer; FOIS functional oral intake scale
aTumor sites including the nasal cavity or paranasal sinuses are reported as ‘Other location’